Navigation Links
Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
Date:2/7/2008

SEATTLE, Feb. 7 /PRNewswire/ -- Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced the appointment of David Drajeske as Director of Business Development.

Drajeske brings more than a decade of business development experience in the life sciences industry. He formerly served as Vice President of Business Development for Helix BioMedix, a publicly traded biotechnology company, from 2004 to 2006. While at Helix, Drajeske was involved in the initiation and negotiation of multiple development collaborations. Prior to Helix, Drajeske served as Manager of Business Development for Immunex Corporation. He has also served as Senior Manager, Business Development and Alliance Management for Thermogen, Inc. and Medichem Life Sciences. Drajeske received an M.S. in Biotechnology from Northwestern University's Kellogg Center for Biotechnology and a B.S. in chemical engineering from Purdue University.

"David will be instrumental in our outreach activities aimed at educating potential partners about Koronis' innovative Viral Decay Acceleration therapeutics," said Donald Elmer, Chairman and interim Chief Executive Officer of Koronis. "His business development experience will be an asset to our Company."

About Koronis

Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate, KP-1461 for the treatment of human immunodeficiency virus (HIV), is currently being evaluated in a Phase 2 trial. In addition to KP-1461, the Company has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit http://www.koronispharma.com.


'/>"/>
SOURCE Koronis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
2. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
5. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
10. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
11. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016  In ... Society of Hematology (ASH) Annual Meeting and Exposition in ... advanced biomedical engineering methods to improve the delivery of ... conditions. These new methods are designed to carry therapies ... are needed most, which could provide a substantial advantage ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... tube systems for North American hospitals, will present its chain-of-custody solution for tracking ... Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the "Biometrics ... The report forecasts the biometrics market ... CAGR of 12.28% during the period 2016-2020. The ... inputs from industry experts. The report covers the market landscape and ... a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
Breaking Biology News(10 mins):